Charles River Laboratories analyst calls stay supportive, shares with a clear Wall Street consensus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 13:53.

Charles River Laboratories (US1591881009) continues to draw active analyst attention on the NASDAQ. Recent research highlights a supportive rating profile despite earlier full-year guidance adjustments, according to several update notes from mid-May and June 2026.

What analysts say today

According to a June 17, 2026 summary of Wall Street views, Morgan Stanley upgraded Charles River Laboratories from Equal-Weight to Overweight, citing improving biopharma funding trends and a constructive demand outlook for preclinical services. The same aggregation shows 12 tracked analyst ratings, with 9 Buy and 3 Hold recommendations and no Sell calls, pointing to a clearly positive consensus stance on the shares.

The May 8, 2026 review of the company’s first-quarter 2026 figures notes that Charles River Laboratories reported Q1 results above consensus earnings expectations but paired the beat with a more cautious full-year 2026 forecast. In that update, the tone from covering analysts remained broadly constructive, describing the combination of robust near-term execution and a more conservative guidance backdrop as manageable for long-term holders.

Consensus on the Charles River stock

In the same mid-June consensus snapshot, the average Wall Street price target for Charles River Laboratories is reported above the prevailing market level, with the sample pointing to expected upside from current trading around the low 200 dollar area. While individual target figures vary by house, the spread between the lowest and highest targets illustrates differing views on how quickly demand in outsourced research and safety assessment will normalize.

The distribution of 9 Buy and 3 Hold recommendations in that dataset implies that a clear majority of analysts see the stock as attractive at present valuations. The absence of active Sell ratings in the reviewed sample underscores that, even after the more cautious full-year guidance, larger research houses broadly frame the shares as a core exposure to contract research services rather than a name to avoid.

The business behind the stock

Charles River Laboratories generates its revenue primarily by providing outsourced research and development services to pharmaceutical and biotechnology companies, with a focus on preclinical testing, safety assessment and related laboratory services. The company’s model is built on long-term relationships with drug developers that rely on Charles River for essential animal models, laboratory capacity and regulatory-compliant study execution in early-stage pipelines.

Where the Charles River shares trade

Charles River Laboratories shares (US1591881009) trade on NASDAQ under the ticker CRL. As of 2026-06-25, 16:00 ET, recent market commentary places the stock close to the 202 dollar mark in regular-session trading, with a market capitalization that reflects its role as a mid-cap component of the US health care services universe on the S&P 500.

Disclaimer: This article provides neutral, fact-based information on the Charles River Laboratories shares and does not contain any investment advice, buy or sell recommendation, or individualized financial guidance.